AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25800045
Drug: Topical Citrullus
RxNorm normalized name: Citrullus colocynthis fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Citrullus colocynthis extract oil
Trial: 22781295
Drug: LACJ therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LACJ therapy (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + Jinghuaweikang 3 capsules)
Trial: 22781295
Drug: LACB therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LACB therapy (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + bismuth potassium citrate 220 mg)
Trial: 22781295
Drug: LAC therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC therapy (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg)
Trial: 22781295
Drug: LACJ therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LACJ therapy
Trial: 22781295
Drug: LACB therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LACB therapy
Trial: 22781295
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of antibiotic-resistant genes
Trial: 8894500
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg NN623
Trial: 8894500
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg A4166
Trial: 8894500
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg NN623
Trial: 6804161
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives with 50 micrograms or less of ethinyl estradiol
Trial: 6804161
Drug: Preparation containing
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation containing 20 micrograms ethinyl estradiol
Trial: 6804161
Drug: Preparation containing
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation containing 400 micrograms norethisterone acetate
Trial: 6804161
Drug: Norethisterone preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone preparations
Trial: 6804161
Drug: Levonorgestrel-containing preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel-containing preparations
Trial: 25559915
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training three times weekly
Trial: 19893122
Drug: Therapeutic education
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic education on CHF topics (general information, symptoms, dietary nutrition, medicative therapy)
Trial: 11795438
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg/day) for 3 months
Trial: 9501267
Drug: Phenylalanine‐complemented amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylalanine‐complemented amino acid supplement (increased blood phenylalanine concentrations to 1000-1300 mumol/L for 3 months)
Trial: 1098358
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (2000 international units daily for 3 months)
Trial: 20337618
Drug: ramosetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramosetron 0.3 mg (n = 42)
Trial: 20337618
Drug: ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 4 mg (n = 42)
Trial: 3596789
Drug: Inclusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclusion of the beta-blocker oxprenolol
Trial: 29019894
Drug: Late-course concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late-course concurrent chemoradiotherapy (CCRT)
Trial: 29019894
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (SCRT)
Trial: 29019894
Drug: Late-course concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late-course concurrent chemoradiotherapy (CCRT) in pT3-4 pN1-3 cM0 subgroup
Trial: 29019894
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (SCRT) in pT3-4 pN1-3 cM0 subgroup
Trial: 21733566
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Catumaxomab (10, 20, 50, and 100 μg)
Trial: 21733566
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Catumaxomab (10 μg)
Trial: 19811362
Drug: GABA-rich Chlorella
RxNorm normalized name: Chlorella emersonii extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA-rich Chlorella (20 mg as gamma-aminobutyric acid)
Trial: 9754979
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide 1.2 mg twice daily
Trial: 7828695
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (800 micrograms.day‐1)
Trial: 27521028
Drug: no laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no laser treatment (control group)
Trial: 21442808
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (Tianqi Tongjing Capsule)
Trial: 16474093
Drug: Praziquantel treatment
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel treatment for both humans and buffaloes in Jishan
Trial: 16474093
Drug: Praziquantel treatment
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel treatment for humans only in Hexi
Trial: 16474093
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for buffaloes in Jishan
Trial: 8495764
Drug: Danazol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (600 mg/d)
Trial: 3120167
Drug: stress tests
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stress tests (insulin‐induced hypoglycaemia/glucagon)
Trial: 27696440
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg raltegravir (q.d.) alone
Trial: 27696440
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg raltegravir co-administered with 400 mg atazanavir (q.d.)
Trial: 27696440
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg atazanavir (q.d.)
Trial: 22571342
Drug: MG98 125
RxNorm normalized name: MG98
DrugBank: MG98 (DB06544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG98 125 mg/m2 with Interferon-α-2β 9 MIU (continuous schedule)
Trial: 22571342
Drug: MG98 200
RxNorm normalized name: MG98
DrugBank: MG98 (DB06544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG98 200 mg/m2 with Interferon-α-2β 9 MIU (intermittent schedule)
Trial: 20861218
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplements (LNS) 43 g/d for 12 weeks
Trial: 20861218
Drug: Corn-soy blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn-soy blend (CSB) 71 g/d for 12 weeks
Trial: 16133554
Drug: 0.2 g
RxNorm normalized name: methionine 0.2 gram ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g BBR three times daily for 3 months
Trial: 16133554
Drug: CsA without
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA without BBR co-administration
Trial: 12177103
Drug: Combined induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined induction and radiotherapy (HFEBRT at a dose of 72 Gy)
Trial: 12177103
Drug: Response to
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response to chemotherapy
Trial: 1977258
Drug: Cyclosporin A,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A, 5 mg/kg/day for 10 days
Trial: 20737165
Drug: Caffeine (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (240 mg) via chewing gum
Trial: 18831749
Drug: Echinacea purpurea
RxNorm normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea purpurea (alcohol extract) administered for 10 days at the first sign of each common cold
Trial: 18831749
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) including cranial manipulation, with up to five visits over 3 months
Trial: 11841372
Drug: 3.0% diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0% diclofenac in 2.5% hyaluronan gel for 60 days
Trial: 11841372
Drug: 3.0% diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0% diclofenac in 2.5% hyaluronan gel for 30 days
Trial: 11841372
Drug: Placebo (2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2.5% hyaluronan gel) for 60 days
Trial: 11841372
Drug: Placebo (2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2.5% hyaluronan gel) for 30 days
Trial: 10080462
Drug: Sibrafiban (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibrafiban (oral, selective antagonist of platelet glycoprotein IIb/IIIa receptor)
Trial: 7672773
Drug: Aluminium phosphate
RxNorm normalized name: Aluminium phosphate
DrugBank: Aluminium phosphate (DB14517)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aluminium phosphate gel (11 g five times a day)
Trial: 7672773
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg once daily for 6 weeks)
Trial: 7672773
Drug: Aluminium phosphate
RxNorm normalized name: Aluminium phosphate
DrugBank: Aluminium phosphate (DB14517)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aluminium phosphate gel
Trial: 3966685
Drug: Chlorpheniramine maleate
RxNorm normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine maleate (10 mg)
Trial: 30898502
Drug: Prophylactic incisional
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic incisional negative pressure wound therapy (iNPWT)
Trial: 21367355
Drug: Lamotrigine (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (titrated to a maximum of 400 mg/d for 10 weeks)
Trial: 15156253
Drug: Aescin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aescin and essential phospholipids (AEPL) gel
Trial: 11839116
Drug: 12 group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 group sessions (twice a month)
Trial: 7593457
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal estradiol (50 ug/24 hrs) with periodic medroxyprogesterone (10.0 mg/day) (n = 13)
Trial: 7593457
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral estradiol (2.0 mg/day) and continuous norethisterone acetate (1.0 mg/day) (n = 13)
Trial: 28388994
Drug: Baseline hemoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline hemoglobin <12 g/dl in women or <13 g/dl in men (anemia)
Trial: 25879863
Drug: Sertraline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (75 mg/day) plus deanxit (one piece/day)
Trial: 25879863
Drug: Sertraline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (75 mg/day) plus placebo (one piece/day)
Trial: 21463215
Drug: Oral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glutamine (0.3 g/kg/day, n = 51-Gln group)
Trial: 15038804
Drug: Medication Alliance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Alliance training program
Trial: 7840516
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methotrexate followed by 5‐Fluorouracil and leucovorin rescue on day 1 (Arm A)
Trial: 24961091
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of 0.5% betaxolol and 0.2% brimonidine
Trial: 21421493
Drug: G‐CSF (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (600 µg/day) for 7 consecutive days
Trial: 21421493
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (medication and interventional therapy)
Trial: 19266831
Drug: Ropivacaine 0.8
RxNorm normalized name: ROPivacaine 0.8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.8 mg.kg(‐1) at 1 mg.ml(‐1) (0.8 ml.kg(‐1)) in G1 group
Trial: 19266831
Drug: Ropivacaine 0.8
RxNorm normalized name: ROPivacaine 0.8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.8 mg.kg(‐1) at 2 mg.ml(‐1) (0.4 ml.kg(‐1)) in G2 group
Trial: 17885570
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) (n = 19)
Trial: 11719029
Drug: Vaccinia melanoma
RxNorm normalized name: vaccinia virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinia melanoma oncolysate (VMO) therapy
Trial: 11719029
Drug: Control vaccinia
RxNorm normalized name: vaccinia virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccinia virus (V) therapy
Trial: 11719029
Drug: ECOG and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECOG and Mayo treatment arms
Trial: 9593234
Drug: Preoperative high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative high-dose radiotherapy (5 x 5 Gy)
Trial: 7874153
Drug: Carbohydrate-electrolyte solution
RxNorm normalized name: CARBOHYDRATE/ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-electrolyte solution (C)
Trial: 3606231
Drug: BSHGH (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSHGH (0.1 mg/kg/24 h)
Trial: 27031181
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg daily for 28 days
Trial: 23178468
Drug: Somatostatin administration
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin administration (infused 1 day before operation and continued for 7 days after surgery)
Trial: 21436689
Drug: lotrafilcon B/polyhexamethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lotrafilcon B/polyhexamethylene biguanide (PHMB)‐based multipurpose (MPS) solution (MPS‐1)
Trial: 21436689
Drug: lotrafilcon B/polyquaternium‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lotrafilcon B/polyquaternium‐1 and myristamidopropyl dimethylamine‐based solution (MPS‐2)
Trial: 21436689
Drug: lotrafilcon B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lotrafilcon B and another PHMB‐based solution (MPS‐3)
Trial: 12941723
Drug: Pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 45 mg once daily for 16 weeks
Trial: 10960381
Drug: Morphine (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (administered via retrobulbar catheter)
Trial: 8977350
Drug: Flumazenil (0.4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.4, 0.8, and 1 mg bolus injections followed by 1 mg/h infusion for three hours)
Trial: 8977350
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three sequential bolus injections followed by placebo infusion)
Trial: 27473050
Drug: Low tidal-volume
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal-volume ventilation (6 mL•kg(‐1) ideal body weight) with PEEP of 3 cm H2O
Trial: 27473050
Drug: Conventional tidal-volume
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional tidal-volume ventilation (12 mL•kg(‐1) ideal body weight) with PEEP of 3 cm H2O
Trial: 24680265
Drug: Thrombus aspiration
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombus aspiration and intracoronary tirofiban combined with nitroprusside bolus (200 µg prior to the first balloon inflation, Group C)
Trial: 24680265
Drug: Thrombus aspiration
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombus aspiration and intracoronary tirofiban bolus (25 µg/kg prior to the first balloon inflation, Group B)
Trial: 19144653
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Angiotensin-converting enzyme inhibitors + Angiotensin receptor blockers)
Trial: 17256447
Drug: Psychotropic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic drugs (antidepressants and/or benzodiazepines)
Trial: 15992236
Drug: Static magnets
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Static magnets (after excluding inadequate treatment studies)
Trial: 12162471
Drug: GW433908G tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW433908G tablet
Trial: 12162471
Drug: GW433908G suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW433908G suspension
Trial: 12162471
Drug: GW433908G tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW433908G tablets
Trial: 12162471
Drug: amprenavir capsules
RxNorm normalized name: amprenavir Oral Capsule
DrugBank: Amprenavir (DB00701)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: amprenavir capsules
Trial: 9475647
Drug: Phosphagen HP
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphagen HP with 15.75 g x d(‐1) of HPCE pure creatine monohydrate (HP)
Trial: 8751030
Drug: Homeopathic after-bite
RxNorm normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Homeopathic after-bite gel
Trial: 8751030
Drug: Homeopathic after-bite
RxNorm normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Homeopathic after-bite gel vs Untreated spots
Trial: 8751030
Drug: Homeopathic after-bite
RxNorm normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Homeopathic after-bite gel vs Placebo gel
Trial: 8751030
Drug: Homeopathic after-bite
RxNorm normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Homeopathic after-bite gel vs No treatment (pooled data)
Trial: 8751030
Drug: Homeopathic after-bite
RxNorm normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Homeopathic after-bite gel vs Placebo gel (pooled data)
Trial: 8751030
Drug: Extent of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extent of itching after treatments
Trial: 2210982
Drug: Parenteral piperacillin
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral piperacillin alone (Group B, n = 22)
Trial: 2210982
Drug: Piperacillin in
RxNorm normalized name: piperacillin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin in combination with povidone-iodine enema (Group C, n = 25)
Trial: 345198
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg aspirin (ASA)
Trial: 25730053
Drug: 50 U/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 U/mL BTX‐A injection
Trial: 25730053
Drug: 25 U/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 U/mL BTX‐A injection
Trial: 25730053
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (50 U/mL and 25 U/mL BTX‐A)
Trial: 25730053
Drug: High-concentration group
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration group (50 U/mL)
Trial: 25730053
Drug: Low-concentration group
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-concentration group (25 U/mL)
Trial: 24095604
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention regarding anxiety and satisfaction (oral and written information on safety, risks, and benefits of haemotherapy)
Trial: 19699838
Drug: 113 g
RxNorm normalized name: UREA 40 g in 113 g TOPICAL GEL [Bare 40 Plus HA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 113 g serving of 90% lean beef (30 g protein)
Trial: 19699838
Drug: 340 g
RxNorm normalized name: ALCOHOL 0.7 g in 340 g TOPICAL LOTION [Moxe]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 340 g serving of 90% lean beef (90 g protein)